THE INVIVO ANTITUMOR EFFECT OF HUMAN RECOMBINANT INTERLEUKIN-6
THE INVIVO ANTITUMOR EFFECT OF HUMAN RECOMBINANT INTERLEUKIN-6
复制标题
DOI：
10.1111/j.1349-7006.1990.tb03342.x
复制
发表时间：
1990-10-01
期刊：
影响因子：
--
通讯作者：
OKADA, M
中科院分区：
文献类型：
--
作者：
KITAHARA, M;KISHIMOTO, S;OKADA, M
重组白介素6(IL-6)可在体内诱导C57BL/6小鼠淋巴细胞和腹膜渗出细胞(PEC)产生抗同基因可移植红白血病(FBL-3)的细胞毒性T淋巴细胞(CTL)。此外，16只C57BL/6小鼠中有15只注射了5倍。经5次处理后，有106个存活的FBL-3细胞存活至100天。肿瘤细胞接种后第1、2、3、5、7、9天分别给予104U重组IL-6，3次/d，治愈率为94%。治愈的小鼠在重新接种大量活的FBL-3细胞后，可以迅速排斥肿瘤细胞。在这些治愈的小鼠中，FBL-3细胞在体内或体外再次刺激PEC、脾和淋巴结细胞可产生FBL-3特异性的CD4-8+CTL细胞，但从未产生淋巴因子激活的杀伤细胞。提示IL-6的抗肿瘤作用是通过体内诱导肿瘤特异性CTL实现的。
Administration of recombinant interleukin-6 (IL-6) was found to induce in vivo generation of cytotoxic T lymphocytes (CTL) against syngeneic transplantable erythroleukemia (FBL-3) in lymph node cells and peritoneal exudate cells (PEC) in C57BL/6 mice. Furthermore, 15 out of 16 C57BL/6 mice injected with 5 .times. 106 viable FBL-3 cells survived on day 100 when they were treated with 5 .times. 104 U of recombinant IL-6 three times a day on days 1, 2, 3, 5, 7 and 9 after the inoculation of tumor cells (the cure rate was 94%). Cured mice could reject the tumor cells rapidly after the re-inoculation of a large number of live FBL-3 cells. In contrast, all normal mice died of tumor development by day 10. In these cured mice, FBL-3-specific CD4-8+ CTL cells were found to be generated in PEC, spleen and lymph node cells by either in vivo or in vitro re-stimulation with FBL-3 cells, but lymphokine-activated killer cells never developed. The results suggested that the anti-tumor effect of IL-6 was mediated by in vivo induction of tumor-specific CTL.